Evidence map›Paper›PMID 42386770›Full record

ArticleNPJ vaccines2026

Safety and immunogenicity of concomitant quadrivalent meningococcus ACYW-TT and meningococcus group B vaccines.

Monica A McArthur, Adam Finn, Lawrence Barnes, Richard Burkimsher, Katrina Cathie, Eva Galiza, Paul Heaton, Nicholas Jacobsen, Stephen Jones, Sian Ludman and 13 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03632720 (Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Using a 1+1 Schedule in a National Immunization Schedule Having a Meningococcal Group B Vaccine as Standard of Care), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03632720 phase3completednot on this map

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Using a 1+1 Schedule in a National Immunization Schedule Having a Meningococcal Group B Vaccine as Standard of Care

TypeinterventionalSponsorSanofi Pasteur, a Sanofi CompanyRan2018 to 2022Enrolled788ConditionsHealthy Volunteers (Meningococcal Infection)ArmsMeningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine, Meningococcal group B vaccine, Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine, Human rotavirus RIX4414 strain vaccine, Pneumococcal 13-valent polysaccharide conjugate vaccine
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Monica A McArthurGlobal Clinical Development Strategy, Sanofi, Swiftwater, PA, USA. monica.mcarthur@sanofi.com.
Adam FinnBristol Vaccine Centre, Schools of Population Health Sciences and Cellular and Molecular Medicine, University of Bristol and Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Lawrence BarnesRame Medical Limited, Penntorr Health, Torpoint, Cornwall, UK.
Richard BurkimsherMounts Bay Medical Ltd, Connor Downs Surgery, Connor Downs, Hayle, Cornwall, UK.
Katrina CathieNational Institute for Health Research Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
Eva GalizaVaccine Institute, City St George's, University of London, London, UK.
Paul HeatonDepartment of Paediatrics, Yeovil District Hospital, Yeovil, Somerset, UK.
Nicholas JacobsenNewquay Health Centre, Newquay, Cornwall, UK.
Stephen JonesRoyal United Hospital, Combe Park, Bath, Avon, UK.
Sian LudmanRoyal Devon University Hospital, Exeter, UK.
Patrick MooreThe Adam Practice, Poole, Dorset, UK.
Clare MurrayRoyal Manchester Children's Hospital, Manchester University NHS Foundation Trust, and Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Manchester, UK.
Daniel OwensNational Institute for Health Research Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
Alexander TrotmanChaddlewood Surgery, Plympton, Plymouth, UK.
Ray BorrowVaccine Evaluation Unit, UK Health Security Agency, Manchester, UK.
Julie ChaixGlobal Clinical Immunology, Sanofi, Marcy l'Etoile, France.
Arlette DelgadoGlobal Pharmacovigilance-Vaccines, IQVIA; and Patient Safety & Pharmacovigilance, Sanofi, Madrid, Spain.
Estelle DuboisGlobal Clinical Operations, Sanofi, Marcy l'Etoile, France.
Youjun HuangEvidence Generation and Decision Sciences, Sanofi, Chengdu, China.
Olga SyrkinaPatient Safety and Pharmacovigilance, Sanofi R&D, Cambridge, MA, USA.
Betzana ZambranoGlobal Clinical Development Strategy, Sanofi, Montevideo, Uruguay.
Mandeep Singh DhingraGlobal Clinical Development Strategy, Sanofi, Swiftwater, PA, USA.
Christine RehmGlobal Clinical Development Strategy, Sanofi, Swiftwater, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infants are vulnerable to meningococcal disease. In this open-label phase III study (NCT03632720; registered 13/8/2018), infants were randomised to quadrivalent ACWY conjugated vaccine, MenACYW-TT, at 3 and 12-13 months and four-component meningococcus group B vaccine (4CMenB) at 2, 4, and 12-13 months (Group 1), MenACYW-TT at 3 and 12-13 months and 4CMenB at 2 and 4 months (Group 2), or 4CMenB at 2, 4, and 12-13 months (Group 3). Routine vaccines were also administered per UK schedule. Primary outcome of non-inferiority of seroprotection rates against the four capsular groups (A, C, W, and Y) in Group 1 versus Group 2 at day 30 after the second vaccine dose was demonstrated with seroprotection rates ≥99% against all capsular groups in both groups. In Group 3, cross-reactivity was observed, with hSBA titres against capsular groups A and C increasing >10-fold after the third 4CMenB dose. Reactogenicity was consistent with the known profiles of both vaccines; one case of anaphylaxis related to MenACYW-TT was reported and resolved without sequelae. No new safety concerns were identified.

Identifiers

PMID42386770
PMCPMC13687022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.